Rockwell Medical, Inc. — Q1 2024 Form 10-Q
Period: Three months ended March 31, 2024; unaudited. Rockwell develops, manufactures, and distributes hemodialysis products and operates as one reportable segment.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $22.7 million | $19.7 million | +15% |
| Gross profit / margin | $3.1 million / 13.5% | $2.6 million / 13.2% | +18% gross profit |
| Operating loss | $1.3 million | $1.4 million | Loss narrowed by $0.1 million |
| Net loss | $1.7 million | $1.8 million | Loss narrowed slightly |
| Loss per share, diluted | $0.06 | $0.10 | Improved |
| Cash used in operating activities | $2.4 million | $3.9 million | Use decreased by $1.5 million |
Sales growth reflected additional customers from the 2023 Evoqua asset acquisition and price increases, partly offset by $1.5 million of deferred license revenue recognized in Q1 2023. Product revenue was $22.7 million versus $18.1 million. Q1 2023 gross profit included $1.5 million associated with that deferred license revenue recognition.
Cost of sales was $19.6 million, or 86% of sales, compared with $17.1 million, or 87%. Research and product development expense fell to $18,000 from $278,000 as the company paused Triferic R&D. General and administrative expense increased to $3.8 million from $3.3 million, primarily due to wages, administrative costs, and acquired-intangible amortization. Interest expense was $431,000 versus $387,000; net other expense was $407,000 versus $323,000.
Liquidity, debt, and capital
- At March 31, cash and cash equivalents were $6.6 million and available-for-sale investments were $2.0 million; combined liquidity was approximately $8.6 million. Working capital was $11.7 million.
- Total assets were $50.7 million and total liabilities were $30.1 million. The term loan’s carrying amount was $8.3 million, net of issuance costs and discounts; the company also had $2.5 million current and $2.5 million long-term deferred consideration payable for the Evoqua acquisition.
- Q1 cash declined by $2.3 million to $6.6 million. Investing used $0.1 million; financing provided $0.2 million, including $0.6 million of net ATM share proceeds.
- The Innovatus loan amendment provides for interest-only payments for 30 months, potentially 36 months if conditions are met, and extends maturity to January 1, 2029. The stated effective interest rate was 12.0%. The company reported compliance with loan covenants at quarter-end.
- 358,210 shares were sold through the ATM for $0.6 million net proceeds; approximately $10.4 million remained available. The company cautions that future financing may not be available on favorable terms and could dilute shareholders.
Business developments, outlook, and risks
- DaVita represented approximately 44% of Q1 2024 net product sales, down from 48% in Q1 2023, and 19% of accounts receivable at quarter-end. Its amended supply agreement expires December 31, 2024; DaVita may extend it through 2025 at its discretion, subject to notice.
- The company extended its third-party manufacturing agreement for the former Evoqua product line through December 31, 2024 and plans to transfer production to its own facilities by year-end, which management expects to reduce costs.
- Management believes available working capital and expected operational execution are sufficient for at least twelve months from the filing date. This is not a guarantee: the company may need additional capital, and states that failure to execute its plans or raise funds could require it to curtail operations or cease operations.
- Management identifies customer acquisition, cost containment, and execution of its hemodialysis-concentrates growth strategy as priorities. No numerical revenue, earnings, or margin guidance is provided.
- Risks include reliance on DaVita, financing availability and potential dilution, loan-covenant compliance, manufacturing and supply-chain execution, and macroeconomic uncertainty. The company reported no material change to the risk factors in its 2023 Form 10-K. Routine legal proceedings were not expected to have a material effect.
Investor verification points
- Track cash burn and whether management’s stated twelve-month liquidity outlook remains supportable, including the timing and terms of any additional financing.
- Verify progress, costs, and timing of the planned transfer of former Evoqua production to Rockwell facilities.
- Monitor DaVita’s purchasing commitments and whether it exercises its option to extend the supply agreement beyond 2024.
- Review debt interest, covenants, and any potential dilution from ATM sales, warrants, options, and convertible preferred stock.
- Assess whether sales growth translates into sustainable gross-margin improvement, given Q1 2023’s deferred-license-revenue comparison and current low operating margin.